Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control

Myeloma is heterogeneous at the molecular level with subgroups of patients characterised by features of epigenetic dysregulation. Outcomes for myeloma patients have improved over the past few decades except for molecularly defined high-risk patients who continue to do badly. Novel therapeutic approa...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Blood Cancer J
Hoofdauteurs: Pawlyn, C, Bright, M D, Buros, A F, Stein, C K, Walters, Z, Aronson, L I, Mirabella, F, Jones, J R, Kaiser, M F, Walker, B A, Jackson, G H, Clarke, P A, Bergsagel, P L, Workman, P, Chesi, M, Morgan, G J, Davies, F E
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Nature Publishing Group 2017
Onderwerpen:
Original Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5380911/
https://ncbi.nlm.nih.gov/pubmed/28362441
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2017.27
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items